Development of Checkpoint 1 Inhibitors and novel diagnostics for Acute Myeloid Leukemia in humans.
| Reference number | |
| Coordinator | Biovica International AB |
| Funding from Vinnova | SEK 1 957 412 |
| Project duration | March 2011 - February 2013 |
| Status | Completed |
Important results from the project
The objective of this project is to develop a novel therapy and companion diagnostics for the treatment of acute myeloic leukemia (AML). Specifically, we will discover a novel CHK1 inhibitor and a diagnostic based on a novel thymidine kinase cell proliferation technology.